Skip to main content
OpenTrials
Completed

NCT Number: NCT04846127

CanGaroo® Registry Study

A Multi-Center Registry Evaluating Participants Who Receive CanGaroo Envelope or No Envelope During their CIED Implantation

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Arkansas Heart Hospital, Little Rock, Arkansas, United States

Loading trial locations.

About this study

This prospective, multi-center study will enroll up to 500 participants who are undergoing their initial CIED implant with either a CanGaroo envelope or no envelope.

Once a participant is enrolled in one of the two cohorts, each participant will have their medical history data reviewed and data will be recorded in the CRF including baseline demographics, medications, and diagnoses.

The details of the CIED procedure including any complications/AEs that occur during the procedure will be captured on the appropriate CRF.

Information collected at the follow-up visits will include documentation of post-procedure status, including any complications, adverse events, or revision/reoperation procedures that occur during the follow-up period. This information will also be collected for any unscheduled follow-ups, visits, or care encounters that occur up to 3 months post-procedure. For participants that agree and qualify for optional long-term follow-up, the same information will be collected at additional follow-up points every six months for up to five years.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants for whom this is their first CIED implantation at a particular anatomical site.

Participants with a history of prior CIED implants at other anatomical sites than the current site can be included, provided that the planned implant location for the current CIED procedure is the first implant procedure at that site.

  • Participants aged 18 years or older at time of enrollment.
  • Participant is able and agrees to provide written informed consent and use of PHI.

Exclusion criteria

  • Participants who have had one or more prior CIED procedures (implantations or revisions) at the current device implant site.
  • Participants under the age of 18 at time of enrollment.

Treatment and study plan

CanGaroo Envelope

Device

Utilization of a CanGaroo envelope with the CIED during the participant's CIED implant procedure.

Primary outcomes

  1. Association between participant characteristics and outcomes

    Time frame: 3 months post-procedure

    Cohort comparison of clinically significant factors such as physical and demographic characteristics, medical history risk factors related to post-procedure events, and associations with outcomes and events.

  2. Association between CanGaroo envelope use and CIED implant-related outcomes and events.

    Time frame: 3 months post-procedure

    Cohort comparison of clinically significant events such as infection, wound healing issues, CIED migration, CIED erosion, or a revision/reoperation procedure.

Sponsors and collaborators

Lead sponsor

Elutia Inc.

Industry

Registry information

Official study title

A Multi-Center Registry Evaluating Participants Who Receive CanGaroo® Envelope or No Envelope During CIED Implantation

Important dates

Study start
2021
Primary completion
2023
Study completion
2024
First posted
Apr 15, 2021
Registry last updated
May 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.